Here we provide the updated version of the guidelines of the European Association for
Palliative Care (EAPC) on the use of opioids for the treatment of cancer pain. The update …

BACKGROUND Some patients with cancer pain may develop uncontrolled adverse effects,
including generalized myoclonus, delirium, nausea and emesis, or severe sedation before …

▪ Abstract Summary of consensus: 1. The use of opioids in cancer pain: The criteria for
selecting analgesics for pain treatment in the elderly include, but are not limited to, overall …

Objectives: To compare patients' preference for transdermal fentanyl or sustained release
oral morphine, their level of pain control, and their quality of life after treatment. Design …

Fentanyl is a synthetic opioid with short-acting analgesic activity after intravenous or
subcutaneous administration. The low molecular weight, high potency and lipid solubility of …

Transdermal delivery allows continuous systemic application of opioids through the intact
skin. This review analyses the pharmacokinetic properties of transdermal opioid …

Fentanyl is a synthetic opioid agonist which interacts primarily with the μ-opioid receptor.
The low molecular weight, high potency and lipid solubility of fentanyl make it suitable for …

Objective: To discuss the historical basis and limitations of opioid conversion tables, review
the relevant literature, and establish an evidence-based equianalgesic dose ratio (EDR) …

Direct conversion from oral morphine to transdermal fentanyl with a ratio of oral
morphine/transdermal fentanyl (100: 1 mg) daily was examined in patients with cancer pain …

Background: Buprenorphine is a potent opioid analgesic that is available in sublingual and
parenteral formulations. A new formulation, buprenorphine transdermal delivery system …